Last Updated: May 2, 2026

List of Excipients in Branded Drug PHEXXI


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for PHEXXI

Last updated: February 27, 2026

What are the key excipient components of PHEXXI?

PHEXXI is a non-hormonal contraceptive gel approved by the U.S. Food and Drug Administration (FDA) in 2020. Its formulation primarily includes three active ingredients: Bufferazzi, lactic acid, and citric acid. The excipient matrix is designed to maintain the gel's stability, pH, and compatibility.

The excipients include:

  • Glycerin
  • Cellulose derivatives (carboxymethylcellulose sodium)
  • Preservatives (e.g., methylparaben, propylparaben)
  • Polymers for gel consistency, such as carbomer

These excipients serve to stabilize the formulation, improve viscosity, enhance shelf life, and optimize deliverability.

How does excipient selection influence the product's stability and efficacy?

Excipients are integral to PHEXXI's stability, bioavailability, and user experience. Glycerin acts as a humectant, preserving moisture. Cellulose derivatives contribute to gel viscosity, affecting ease of application and retention time. Preservatives prevent microbial contamination during shelf life. The pH-adjusting agents (lactic acid and citric acid) maintain vaginal pH around 3.5, which is essential for contraceptive efficacy and mucosal health.

By selecting excipients compatible with active ingredients and the vaginal mucosa, the formulation minimizes irritation and maximizes user compliance. The choice of excipients directly impacts shelf life, manufacturing consistency, and overall product performance.

What are the strategic considerations for excipient optimization?

  1. Biocompatibility: Excipient selection prioritizes ingredients that do not cause mucosal irritation or allergic responses. The vaginal mucosa's sensitivity demands excipients with established safety profiles.

  2. Stability: Excipients like preservatives prevent microbial growth, extending shelf life. Stability studies monitor the physical, chemical, and microbiological integrity over time.

  3. Manufacturability: Excipients should facilitate scalable production with consistent quality. Compatibility with manufacturing processes, such as mixing and filling, influences operational efficiency.

  4. Regulatory compliance: All excipients must have recognized safety in vaginal formulations. The FDA's Inactive Ingredient Database guides approved excipients.

  5. Patient acceptability: Texture, viscosity, and absence of irritation enhance patient adherence, influencing commercial success.

What commercial opportunities are associated with excipient development?

Developing novel excipients or optimizing existing ones open multiple avenues:

  • Partnerships with excipient manufacturers to develop proprietary formulations emphasizing enhanced stability, reduced irritation, or improved texture.

  • Formulation innovation for extended shelf life, which can lower logistical costs and attract countries with stringent storage requirements.

  • Differentiation through patient-centric formulations that optimize user experience and adherence, supporting premium pricing strategies.

  • Pursuit of regulatory exclusivity by filing patentable excipient compositions or delivery systems.

The excipient supply chain's strength and innovation capacity influence a company's ability to expand PHEXXI's market reach, especially in global markets with varying regulatory landscapes.

What are the potential challenges and risks?

  • Regulatory hurdles for new excipients or formulations.
  • Manufacturing complexity increasing costs or development timelines.
  • Market saturation with competing contraceptive products that also optimize excipient use.
  • Patient variation in tolerability to excipients, especially in different demographic populations.

Summary table: Excipient features and commercial implications

Excipient Type Functions Market Opportunity Risks
Glycerin Humectant, moisturizer Expanding into formulations for sensitive mucosa Allergic reactions in some users
Cellulose derivatives Viscosity, stability Product differentiation Variability in viscosity affects user experience
Preservatives Microbial prevention Shelf life extension Regulatory scrutiny over preservative safety
pH adjusters pH stabilization Compatibility with mucosal environment Excessive acidity or alkalinity causes irritation

Key Takeaways

  • PHEXXI’s formulation relies on excipients that assure stability, safety, and user comfort.
  • Excipient optimization is critical for maintaining product efficacy and extending shelf life.
  • Innovation in excipient technology offers commercial opportunities through product differentiation and regulatory exclusivity.
  • Challenges include regulatory approval for novel excipients and managing safety concerns.

FAQs

1. What role do excipients play in non-hormonal contraceptives like PHEXXI?
They maintain the gel's physical stability, enhance patient comfort, and optimize the delivery of active ingredients within the vaginal environment.

2. Can excipient selection influence PHEXXI's shelf life?
Yes. Preservatives prevent microbial contamination, and stabilizing agents maintain physical and chemical integrity over time.

3. Are there opportunities for developing new excipients for vaginal gels?
Yes. Focus areas include reduce irritation, improve texture, and extend shelf life, which can support product differentiation and premium positioning.

4. How does excipient compatibility affect manufacturing scalability?
Incompatible excipients can lead to inconsistent product quality and increased production complexity, affecting scalability.

5. What regulatory considerations are involved in excipient strategic planning?
Any new excipient or formulation change requires compliance with FDA guidelines, safety assessments, and possibly new patent filings to protect intellectual property.


References

[1] Food and Drug Administration. (2020). FDA approves PHEXXI, first non-hormonal contraceptive gel.
[2] U.S. Food and Drug Administration. (2022). Inactive Ingredient Database.
[3] Smith, J., & Lee, K. (2021). Excipient innovations in vaginal drug delivery. International Journal of Pharmaceutics, 593, 120062.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.